Cargando…

HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK

BACKGROUND: Darunavir is considered to have a high genetic barrier to resistance. Most darunavir-associated drug resistance mutations (DRMs) have been identified through correlation of baseline genotype with virological response in clinical trials. However, there is little information on DRMs that a...

Descripción completa

Detalles Bibliográficos
Autores principales:	El Bouzidi, Kate, White, Ellen, Mbisa, Jean L., Sabin, Caroline A., Phillips, Andrew N., Mackie, Nicola, Pozniak, Anton L., Tostevin, Anna, Pillay, Deenan, Dunn, David T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5181398/ https://www.ncbi.nlm.nih.gov/pubmed/27856703 http://dx.doi.org/10.1093/jac/dkw343

Ejemplares similares

Protease mutations emerging on darunavir in protease inhibitor-naïve and experienced patients in the UK
por: El Bouzidi, Kate, et al.
Publicado: (2014)

Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial
por: Geretti, Anna Maria, et al.
Publicado: (2015)

Darunavir in experienced patients
por: Sterrantino, G, et al.
Publicado: (2010)

No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom
por: White, Ellen, et al.
Publicado: (2016)

Detection of resistance mutations and CD4 slopes in individuals experiencing sustained virological failure
por: Schultze, Anna, et al.
Publicado: (2014)

First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines
por: El Bouzidi, Kate, et al.
Publicado: (2020)

Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data
por: Stirrup, Oliver T., et al.
Publicado: (2018)

Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV‐1 resistance mutation
por: Stirrup, OT, et al.
Publicado: (2020)

Profile of darunavir in the management of treatment-experienced HIV patients
por: Wolfe, Cameron, et al.
Publicado: (2009)

Darunavir-based dual therapy in HIV experienced patients
por: Sterrantino, Gaetana, et al.
Publicado: (2014)

An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs
por: Smit, Erasmus, et al.
Publicado: (2017)

Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir
por: Neely, Michael, et al.
Publicado: (2009)

Coevolved Multidrug-Resistant HIV-1 Protease and Reverse Transcriptase Influences Integrase Drug Susceptibility and Replication Fitness
por: Martin, Supang A., et al.
Publicado: (2021)

Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance
por: Castro, Hannah, et al.
Publicado: (2012)

2482. Clinical Outcomes of Once-Daily Darunavir in Treatment-Experienced Patients with Darunavir Resistance Associated Mutations Through 48 Weeks of Treatment
por: Rolle, Charlotte-Paige M, et al.
Publicado: (2019)

Determining the Origins of Human Immunodeficiency Virus Type 1 Drug-resistant Minority Variants in People Who Are Recently Infected Using Phylogenetic Reconstruction
por: Mbisa, Jean L, et al.
Publicado: (2019)

Efficacy of a reduced dose of DARUNAVIR/RTV in a cohort of antiretroviral-naïve and experienced HIV-infected patients: a medium-term follow-up
por: Lanzafame, Massimiliano, et al.
Publicado: (2014)

Safety of darunavir/ritonavir (DRV/r) in HIV-1-infected DRV/r-experienced and -naïve patients: analysis of data in the real-world setting in Italy
por: Antinori, Andrea, et al.
Publicado: (2014)

Combination Therapy with Tenofovir Disoproxil Fumarate/Emtricitabine/Elvitegravir/Cobicistat Plus Darunavir Once Daily in Antiretroviral-Naive and Treatment-Experienced Patients: A Retrospective Review
por: Naccarato, Mark J., et al.
Publicado: (2018)

Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART-experienced patients
por: Ignacio Bernardino, Jose, et al.
Publicado: (2014)

Next generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy
por: Dunn, David T., et al.
Publicado: (2018)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
por: Antoniou, Tony, et al.
Publicado: (2017)

Hepatitis B Virus Infection in HIV-Positive Individuals in the UK Collaborative HIV Cohort (UK CHIC) Study
por: Price, Huw, et al.
Publicado: (2012)

Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection
por: Rosso, R, et al.
Publicado: (2009)

Efficacy of once daily darunavir/ritonavir 800/100 mg in PI/r-experienced HIV-1 infected patients with suppressed HIV-1 replication: the RADAR study
por: Ghosn, J, et al.
Publicado: (2010)

Response to antiretroviral therapy (ART): comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with ART naïve women
por: Huntington, Susie, et al.
Publicado: (2014)

The RADAR Study: Week 48 Safety and Efficacy of RAltegravir Combined with Boosted DARunavir Compared to Tenofovir/Emtricitabine Combined with Boosted Darunavir in Antiretroviral-Naive Patients. Impact on Bone Health
por: Bedimo, Roger J., et al.
Publicado: (2014)

Boosted Tipranavir versus Darunavir in Treatment-Experienced Patients: Observational Data from the Randomized POTENT Trial
por: Elgadi, Mabrouk M., et al.
Publicado: (2012)

Effectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patients
por: Mata-Marín, José Antonio, et al.
Publicado: (2015)

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
por: Restelli, Umberto, et al.
Publicado: (2017)

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study
por: Mills, Anthony M., et al.
Publicado: (2019)

Intrapatient Evolutionary Dynamics of Human Immunodeficiency Virus Type 1 in Individuals Undergoing Alternative Treatment Strategies with Reverse Transcriptase Inhibitors
por: Kayondo, Jonathan K., et al.
Publicado: (2015)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Cobicistat/darunavir/cobicistat/darunavir/emtricitabine/tenofovir-alafenamide/darunavir/ritonavir: Various toxicities and off-label use: 9 case reports
Publicado: (2020)

Comparative Effectiveness of Darunavir 1,200 mg Daily and Approved Dosing Strategies for Protease Inhibitor-Experienced Patients
por: Mikula, James M., et al.
Publicado: (2013)

1766. Sustained Viral Suppression with Dolutegravir and Boosted Darunavir Dual Therapy Among Highly Treatment-Experienced Individuals
por: Hawkins, Kellie, et al.
Publicado: (2018)

Combating HIV resistance – focus on darunavir
por: Tremblay, Cécile L
Publicado: (2008)

Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir
por: Jose, Sophie, et al.
Publicado: (2017)

Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients
por: Fabbiani, Massimiliano, et al.
Publicado: (2023)

Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance
por: Geretti, Anna Maria, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_21gc0rfngn9de6g9fo65lsdm1o